StockData

Alnylam Pharmaceuticals vs Jazz Pharmaceuticals

ALNY and JAZZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALNY and JAZZ compare

Alnylam Pharmaceuticals is the larger company, worth 1.3 times as much as Jazz Pharmaceuticals ($21.0B against $15.6B).

On earnings, Alnylam Pharmaceuticals is cheaper: it trades at 8.1× trailing earnings, against 78.4× for Jazz Pharmaceuticals.

Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 13.5% for Jazz Pharmaceuticals).

Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with 4.4% at Jazz Pharmaceuticals.

Alnylam Pharmaceuticals scores higher on the StockData Score (10 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALNYJAZZ
Size and price
Market cap$21.0B$15.6B
Share price$156.50$240.71
Change, 1 year−65.2%70.6%
Change, 5 years−17.0%94.0%
Beta (5Y)0.920.20
Employees2,5002,890
StockData Score
Total score10 (better)7
Valuation score3 (better)0
Growth score22
Performance score33
Health score22
Dividend score00
Valuation
P/E8.1× (better)78.4×
P/S4.2×3.3× (better)
P/B5.8×3.7× (better)
EV/EBITDA16.8× (better)43.1×
P/FCF26.0×9.6× (better)
FCF yield3.8%10.4% (better)
Fair value$296.91$108.40
Margin of safety47.3% (better)−122%
Growth
Revenue growth (TTM)56.2% (better)13.5%
Revenue growth, 5Y average49.8% (better)12.5%
Net income growth (TTM)2137%–
EPS growth (TTM)2308%–
Profitability
Gross margin77.4%–
Operating margin19.5% (better)9.0%
Net margin52.8% (better)4.4%
FCF margin16.1%34.4% (better)
Return on equity127% (better)5.1%
Return on invested capital–4.5%
Financial health
Debt / equity–1.33
Net debt / EBITDA–6.37
Interest coverage3.2×–
Current ratio2.48 (better)1.82
Altman Z-score3.62 (better)1.97
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions99.7%99.2%
Held by insiders0.49%3.4%
Insider net buying, 12 months−$26.3M (better)−$67.1M
Superinvestors holding–1
Short interest, % of float4.1%9.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.